{
  "id": 7409841,
  "title": "Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs",
  "url": "https://urgent.news/2026/09/14/curiumtm-announces-fda-approval-of-bexlutry-lutetium-lu-177-dotatate",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T21:52:01.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/curium-announces-fda-approval-of-bexlutry-lutetium-lu-177-dotatate-injection-for-adults-with-sstr-positive-gep-nets"
  },
  "original_language": "en",
  "account": null,
  "summary": "BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for BEXLUTRY™ lutetium Lu 177 dotatate […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}